Addressing symptom burden in myeloproliferative neoplasms
Authors:
- 11 August 2022
- journal article
- research article
- Published by Elsevier in Best Practice & Research Clinical Haematology
- Vol. 35 (2) , 101372
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (CA054174)
- CTI Biopharma
- Astellas Pharma
This publication has 48 references indexed in Scilit:
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus reportBlood, 2013
- Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled TrialJournal of Clinical Oncology, 2013
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patientsBlood, 2011
- Suppression of inflammation by a synthetic histone mimicNature, 2010
- The Effect of CXCL12 Processing on CD34+ Cell Migration in Myeloproliferative NeoplasmsCancer Research, 2010
- The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosisLeukemia Research, 2009
- Aberrant signal transduction pathways in myeloproliferative neoplasmsLeukemia, 2008
- The burden of fatigue and quality of life in myeloproliferative disorders (MPDs)Cancer, 2006
- Fatigue in long‐term breast carcinoma survivorsCancer, 2006
- Higher Than Normal Plasma Interleukin-6 Concentrations in Cancer Patients With Depression: Preliminary FindingsAmerican Journal of Psychiatry, 2001